JMP Securities began coverage on shares of Novan Inc (NASDAQ:NOVN) in a research report released on Monday morning. The firm issued an outperform rating and a $31.00 target price on the stock.

NOVN has been the topic of several other reports. Wedbush began coverage on Novan in a research report on Monday. They set an outperform rating and a $27.00 price target on the stock. Piper Jaffray Cos. began coverage on Novan in a research report on Monday. They set an overweight rating and a $25.00 price target on the stock.

Shares of Novan (NASDAQ:NOVN) traded up 3.17% on Monday, reaching $21.18. The company’s stock had a trading volume of 18,530 shares. Novan has a 52-week low of $13.77 and a 52-week high of $23.79. The stock has a 50-day moving average of $19.83 and a 200 day moving average of $19.83. The company’s market cap is $51.83 million.

In related news, major shareholder Life Sciences Holdings L. Malin acquired 800,000 shares of the stock in a transaction on Monday, September 26th. The stock was acquired at an average price of $11.00 per share, for a total transaction of $8,800,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Novan Company Profile

Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).

5 Day Chart for NASDAQ:NOVN

Receive News & Stock Ratings for Novan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc and related stocks with our FREE daily email newsletter.